Implications of capecitabine (Xeloda®) for cancer nursing practice

European Journal of Oncology Nursing

Volumn 8, Issue SUPPL. 1, 2004, Pages

  Gerbrecht, Bonnie Mae ^a   Kangas, Tuija ^b  

^a TOM BAKER CANCER CENTRE   (Canada)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Capecitabine; Nursing practice; Oral therapy; Xeloda

Indexed keywords

ANTIINFECTIVE AGENT; CAPECITABINE; DOCETAXEL; FLUCONAZOLE; FLUOROURACIL; FOLINIC ACID; SEROTONIN ANTAGONIST;

ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER STAGING; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; COLORECTAL CANCER; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; HAND FOOT SYNDROME; HEALTH CARE PERSONNEL; HOME CARE; HUMAN; MEDICAL INFORMATION; METASTASIS; NAUSEA; NURSING; OUTPATIENT; PATIENT COMPLIANCE; PATIENT EDUCATION; QUALITY OF LIFE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STOMATITIS; TREATMENT INDICATION;

ADMINISTRATION, ORAL; AMBULATORY CARE; ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; COMMUNICATION; DEOXYCYTIDINE; DOCUMENTATION; DRUG MONITORING; HOME CARE SERVICES; HUMANS; NURSE'S ROLE; NURSING RECORDS; ONCOLOGIC NURSING; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT CARE TEAM; PATIENT EDUCATION; PROFESSIONAL AUTONOMY; TIME FACTORS;

EID: 4444323614     PISSN: 14623889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejon.2004.06.010     Document Type: Article

References (31)

1. C.A.M. Beato M.H. Federico B. Van Eyll S. Cabral M. Perdicaris N.G. Skare S. Lago M.P. Carvalho G.L. Moura R.C. Duarte Effects of capecitabine (X) on quality of life (QoL) in patients (pts) with metastatic colorectal cancer (MCRC) Proceedings of the American Society of Clinical Oncology 23 2004 754 (abstract 8119)
2. A. Birner Pharmacology of oral chemotherapy agents Clinical Journal of Oncology Nursing 7 Suppl 6 2003 11-19
3. M. Borner W. Scheithauer C. Twelves J. Maroun H. Wilke Answering patients' needs: oral alternatives to intravenous therapy Oncologist 6 Suppl 4 2001 12-16
4. T.J. Cantor Waiting lists are putting patients' lives in jeopardy British Medical Journal 321 2000 236
5. J. Cassidy C. Twelves E. van Cutsem P. Hoff E. Bajetta M. Boyer R. Bugat U. Burger A. Garin U. Graeven J. McKendrick J. Maroun J. Marshall B. Osterwalder G. Pérez-manga R. Rosso P. Rougier R.L. Schilsky On behalf of the Capecitabine Colorectal Cancer Study Group First-line oral capecitabine therapy in metastatic colorectal cancer: a favourable safety profile compared with intravenous 5-fluorouracil/leucovorin Annals of Oncology 13 2002 566-575
6. B.R. Cassileth R.V. Zupkis K. Sutton-Smith V. March Information and participation preferences among cancer patients Annals of Internal Medicine 92 6 1980 832-836
7. C. Catania F. Didier A. Sbanotto T. De Pas F. Nole A. Rocca E. Scaffidi C. Robertson J. Bernhard A. Goldhirsch Fully oral chemotherapy regimens: patient's or physician's preference? Proceedings of the American Society of Clinical Oncology 22 2003 777 (abstract 3122)
8. I. Chau S. Legge P. Fumoleau The vital role of education and information in patients receiving capecitabine (Xeloda®) European Journal of Oncology Nursing 8 Suppl. 1 2004 S41-S53
9. J. Corner The role of nurse-led care in cancer management Lancet Oncology 4 2003 631-636
10. S. Faithfull P. Deery Implementation of capecitabine (Xeloda®) into a Cancer Centre UK experience European Journal of Oncology Nursing 8 Suppl. 1 2004 S54-S62
11. C. Ferlini I. Ojima M. Distefano M. Gallo A. Riva P. Morazzoni E. Bombardelli S. Mancuso G. Scambia Second generation taxanes: from the natural framework to the challenge of drug resistance Current Medical Chemotherapy Anti-Cancer Agents 3 2 2003 133-138
12. S.E. Grober R.C. Carpenter M. Glassman D. Blum A comparison of patients' perceptions of oral cancer treatments and intravenous cancer treatments: what the health care team needs to know Proceedings of the American Society of Clinical Oncology 22 2003 746 (abstract 3000)
13. R. James C. Blanco C. Farina Savings in staff time as a result of switching from de Gramont to oral capecitabine for patients with advanced colorectal cancer European Journal of Cancer Supplements 1 5 2003 S83 (abstract 271)
14. S. Junoven S. Lauri New cancer patients: access to information, need for information and participation in decision-making Journal of Cancer Care 5 1996 155-161
15. G. Liu E. Franssen M.I. Fitch E. Warner Patient preferences for oral versus intravenous palliative chemotherapy Journal of Clinical Oncology 15 1 1997 110-115
16. H. Marsé E. Van Cutsem A. Grothey S. Valverde Management of adverse events and other practical considerations receiving capecitabine (Xeloda®) European Journal of Oncology Nursing 8 Suppl. 1 2004 S16-S30
17. J. McKendrick J. Cassidy S. Chakrapee-Sirisuk G. Fountzilas T. Iveson S. Jelic H. Karnicka-Mlodkowska R. Ostojic W. Scheithauer C. Twelves Capecitabine (X) is resource saving compared with i.v. bolus 5-FU/LV in adjuvant chemotherapy for Dukes' C colon cancer patients: medical resource utilization (MRU) data from a large phase III trial (X-ACT) Proceedings of the American Society of Clinical Oncology 23 2004 265 (abstract 3578)
18. M. Mrozek-Orlowski D.K. Frye H.M. Sanborn Capecitabine: nursing implications of a new oral chemotherapeutic agent Oncology Nursing Forum 26 4 1999 753-762
19. V.J. O'Neill C.J. Twelves Oral cancer treatment: developments in chemotherapy and beyond British Journal of Cancer 87 2002 933-937
20. Cervantes P. Fumoleau P. Jones W.Y. Liu L. Mauriac C. Twelves G. van Hazel S. Verma R. Leonard Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results Journal of Clinical Oncology 20 12 2002 2812-2823
21. A.H. Partridge J. Avorn P.S. Wang E.P. Winer Adherence to therapy with oral antineoplastic agents Journal of the National Cancer Institute 94 9 2002 652-661
22. E. Ream A. Richardson The role of information in patients' adaptation to chemotherapy and radiotherapy: a review of the literature European Journal of Cancer Care 5 1996 132-138
23. Revill J. 2003 NHS staff crisis lengthens wait for cancer treatment The Observer Sunday March 23 http://observer.guardian.co.uk/nhs/story/ 0,1480,920078,00.html
24. C. Sainio E. Eriksson Keeping cancer patients informed: a challenge for nursing European Journal of Oncology Nursing 7 2003 39-49
25. J.G.M. Segalla C.T. Oliveira S. Lago S. Cabral R. Ribeiro M. Perdicaris E. Abdo B. Garicochea F.C. Moore C. Fabiani Effect of capecitabine (X) on quality of life (QoL) in patients (pts) with metastatic breast cancer (MBC) Proceedings of the American Society of Clinical Oncology 23 2004 757 (abstract 8130)
26. K. Sikora Developing a global strategy for cancer European Journal of Cancer 35 14 1999 1870-1877
27. M. Simunovic A. Gagliardi D. McCready A. Coates M. Levine D. De Petrillo A snapshot of waiting times for cancer surgery provided by surgeons affiliated with regional cancer centers in Ontario Canadian Medical Association Journal 165 2001 421-425
28. P. Spurgeon F. Barwell D. Kerr Waiting times for cancer patients in England after general practitioners' referrals: retrospective national survey British Medical Journal 320 2000 838-839
29. L. Torrecillas P. Cortes J. Tokunaga C. Aguilar A. Palomo L. Martignon E. Tellez S. Cervantes J. Talavera A. Erazo for the Mexican Oncology Study Group Capecitabine monotherapy or combined with taxanes: early results in quality of life in patients with metastatic breast cancer Proceedings of the American Society of Clinical Oncology 22 2003 749 (abstract 3011)
30. C. Twelves M. Boyer M. Findlay J. Cassidy C. Weitzel C. Barker B. Osterwalder C. Jamieson K. Hieke on behalf of the Xeloda Capecitabine (Xeloda™) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma European Journal of Cancer 37 2001 597-604
31. E. Van Cutsem P.M. Hoff P. Harper R.M. Bukowski D. Cunningham P. Dufour U. Graeven J. Lokich S. Madajewicz J.A. Maroun J.L. Marshall J.L. Mitchell G. Perez-Manga P. Rougier W. Schmiegel J. Schoelmerich A. Sobrero Schilsky Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomized, phase III trials British Journal of Cancer 90 2004 1190-1197